INTRODUCTION
EBP is characterized by recurrent itching and pruritic nodules. In the
case of intense itching, skin becomes fragile, resulting in thickening
and lichenification. In most cases, skin rashes are distributed over
lower extremities, forearms, elbows, dorsum of hands, shoulders, and
lower back, especially the extensor aspect of the extremities.
Baricitinib is a reversible, selective inhibitor of tyrosine protein
kinase, which is capable of modulating the signal transduction of helper
T-cells (Th1, Th2, Th17, and Th22) and might cause many immune-mediated
disorders. EBP is characterized by nodular prurigo-like lichenoid
lesions with intense itching, in addition to the features of DEB, such
as blisters and onychodystrophy.1 Currently, EBP is
treated with topical corticosteroids, tacrolimus, and oral thalidomide,
but the outcomes are often unsatisfactory.2-3Baricitinib is a reversible selective inhibitor of tyrosine protein
kinase, which is capable of modulating the signal transduction of helper
T-cells (Th1, Th2, Th17, and Th22) and participates in many
immune-mediated disorders. Here, one case of baricitinib in the
treatment of EBP is discussed.